Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting

Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors

Iambic’s Rapid Path to the Clinic Enabled by Its AI-Driven Drug Discovery Platform, Built in Collaboration with NVIDIA

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Iambic says new AI model bests AlphaFold as protein models rocket ahead

Iambic Therapeutics Announces New Research with Cover Article in Nature Machine Intelligence Demonstrating the Capabilities of its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

Transforming Computational Drug Discovery with NeuralPLexer2

Iambic Therapeutics expands leadership team with the appointment of Neil Josephson, MD as Chief Medical Officer

Iambic Moves into New HQ